The G7 manufactured by Tosoh Bioscience, Inc., San Francisco, CA, is a fully automated glycohemoglobin analyzer that also offers HbA1c and -thalassemia testing in one platform. Stable HbA1c results are available in 2.2 minutes and -thalassemia results in less than 8 minutes, with quantification of HbF and HbA2. Both systems offer additional features like touch-screen operation and a compact size to conserve counter space.
The circulation of autoantibodies against antigens like insulin provides early markers of autoimmune disease activity. Measurement of these markers has been shown to be valuable in helping health-care providers diagnose and manage their diabetes patients. KRONUS, Inc., Boise, ID, offers a variety of ELISA and RIA kits for the quantitative determination of autoantibodies in serum, like the recently FDA-approved glutamic acid decarboxylase (GAD) Autoantibody RIA Test Kit. Antibodies to GAD have been shown to be the most sensitive single marker for identifying people at risk of developing diabetes.
Available HbA1c analyzers that produce results within minutes are important tools in the detection and management of diabetes. When results are reported during the patient's visit, health-care providers can offer instant feedback and make necessary treatment adjustments. Immediate results mean immediate intervention, resulting in greater diabetes control for both health-care providers and patients.
Beth Wegerbauer is a medical writer and editor with 12 years of experience covering the clinical laboratory field.